

Creating an Optimal Environment for Quality Healthcare for Individuals, Families, and Communities

HHS' CALL TO ACTION ON OPIOID USE DISORDER TREATMENT

Centers for Medicare and Medicaid Services

Office of Program Operations and Local Engagement (OPOLE)



Disclaimer

This information is current at the time of presentation, but the Medicare policy is subject to change. The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. This communication was printed, published, or produced and disseminated at U.S. taxpayer expense.



Office of Program Operations and Local Engagement

Vision:

 Extraordinary staff provide the finest level of service to beneficiaries and consumers, constantly focusing on ways to improve the customer experience and advance program innovation, while effectively collaborating with stakeholders and working with integrity and accountability as we serve the public.

Mission:

 We provide service to millions of CMS beneficiaries & consumers, giving a voice to stakeholders in CMS policy, program development, innovation and implementation. We protect the Nation's trust funds through high quality standards as we uphold the requirements of CMS programs.



✓ ✓

- Increase cohesion & integration across program component regional operations and with program centers and external partners
- Achieve **high performance for customer service** in quality, integrity, consistency, and timeliness
- Conduct local outreach and education to strengthen customer understanding of national policy and Agency initiatives and support expeditious action in emergencies
- Monitor implementation of and provide oversight to CMS contractors to assure compliance with CMS policies and regulations



https://www.cms.gov/about-cms/leadership/organization/office-program-operations-and-local-engagement

CMS 2024 Quality Conference Resilient and Ready Together

Creating an Optimal Environment for Quality Healthcare for Individuals, Families, and Communities



CDR Wanda Pamphile, PharmD, MPH

Robert C. Accetta, RPh, BCGP, FASCP



Karran Phillips, MD, MSc



Megan Meacham, MPH



Conference Resilient and Ready Together

Creating an Optimal Environment for Quality Healthcare for Individuals, Families, and Communities

Patient Safety: Using Data and Resources for Harm Reduction in SNF/PALTC with a Regional Stakeholder Collaborative

Robert C. Accetta, RPh, BCGP, FASCP

Senior Pharmacist,

IPRO, Health Quality Improvement Department

This material was prepared by IPRO, a Quality Innovation Network-Quality Improvement Organization under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. The content presented does not necessarily reflect CMS policy.



The IPRO QIN-QIO

The IPRO QIN-QIO

- A federally-funded Medicare Quality Innovation Network – Quality Improvement Organization (QIN-QIO) in contract with the Centers for Medicare & Medicaid Services (CMS)
- 12 regional CMS QIN-QIOs nationally

IPRO:

New York, New Jersey, and Ohio

Healthcentric Advisors:

Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont

Qlarant:

Maryland, Delaware, and the District of Columbia

Working to ensure high-quality, safe healthcare for **20% of the nation's Medicare FFS beneficiaries**



MA

DE

NY

OH

ME

RI

5

Opioid Crisis Underscores Needs and Points to Opportunities

OPIOID CRISIS AFFECTS PATIENTS AND PROVIDERS

Nearly 117,000 people experienced a non-fatal opioid overdose requiring an emergency department or hospitalization in 2022, per the Centers for Disease Control and Prevention.

- Beneficiaries requiring a hospital admission diagnosed with an opioid overdose or OUD, or experiencing opioid overdose, once stabilized, need placement options for post-acute or extended care services.
- Patients who have OUD and need the level of care provided by SNF/PALTC facilities face challenges to entry.

Abbreviations: QIN-QIO: Quality Innovation Network-Quality Improvement Organization; SNF: Skilled Nursing Facility; PALTC: Post-Acute Long-Term Care; NYS: New York State; DOH: Department of Health; BNE: Bureau of Narcotic Enforcement; OASAS: Office of Addiction Services and Support; OUD: Opioid Use Disorder

CONCERNS TO BE ADDRESSED

- Facilities and clinicians are unfamiliar with providing medications (buprenorphine) or counseling therapy for OUD.
- Facilities have not created relationships with Opioid Treatment Programs (OTPs) which provide methadone for OUD.
- Stigma associated with OUD.
- Access to opioids via external sources.
- Unfamiliarity with emergency protocols to treat suspected opioid overdoses by residents or visitors at facilities.



Quality in Action: Assessments and Planning

RISK ASSESSMENT IN SNF/PALTC SETTING

IPRO assessments identified:

- 29% of nursing homes occasionally, rarely, or never use opioid risk mitigation strategies including naloxone.
- Nearly 20% of nursing homes did not have naloxone in their emergency medication kits.
- 40% of nursing homes desired education on naloxone.

GAP ANALYSIS AND MITIGATION PLANS

Nursing home residents were at increased risk for opioid overdose deaths by both prescription drugs and non-prescribed substances.

Mitigation plans included addressing the following issues:

- emergency medications kits or Automated Dispensing System laws vary by state;
- unavailability of naloxone;
- confusion over multiple naloxone products;
- lack of policies or protocols.



Abbreviations: QIN-QIO: Quality Innovation Network-Quality Improvement Organization; SNF: Skilled Nursing Facility; PALTC: Post-Acute Long-Term Care; NYS: New York State; DOH: Department of Health; BNE: Bureau of Narcotic Enforcement; OASAS: Office of Addiction Services and Support; OUD: Opioid Use Disorder

Underwhelming Activity: Low Naloxone Prescribing

Results indicate very low co-prescribing in both populations. Naloxone is also available through community distribution.

Eligible Fee For Service (FFS) Population

(in FFS for 12 months)

	Total FFS	Had Opioid Prescription	Had Opioid with Naloxone Prescription	% of Opioid with Naloxone Prescription
QIN	6,413,974	764,153	931	0.12%

	Eligible FFS Population (in FFS for 12 months)									
State	Total FFS	Had Opioid Prescription	Had Opioid with Naloxone	% of Opioid with Naloxone						
			Prescription	Prescriptions						
СТ	299,615	35,300	54	0.15%						
DC	59,281	4,917	18	0.37%						
DE	152,998	21,179	23	0.11%						
MA	860,640	113,960	103	0.09%						
MD	802,907	97,974	243	0.25%						
ME	150,122	16,185	54	0.33%						
NH	205,329	21,159	20	0.09%						
NJ	952,273	112,304	125	0.11%						
ОН	1,024,463	139,561	101	0.07%						
RI	90,082	8,984	2	0.02%						
VT	103,523	11,526	13	0.11%						
NY	1,712,741	181,104	175	0.10%						
QIN	6,413,974	764,153	931	0.12%						



An analysis of Medicare beneficiary opioid and naloxone co-prescribing. Data Source: Medicare Fee For Service (FFS) Part D Claims 10-1-22 through 9-30-23. **Eligible Nursing Home (NH) Population**

(in FFS for 12 months)

	Total FFS	Had Opioid Prescription	Had Opioid with Naloxone Prescription	% of Opioid with Naloxone Prescription
QIN	242,174	58,843	149	0.25%

Eligible NH Residents (in FFS for 12 months)									
State	Total FFS	Had Opioid Prescription	Had Opioid with Naloxone Prescription	% of Opioid with Naloxone Prescriptions					
CT	14,924	3,774	10	0.26%					
DC	2,310	379	4	1.06%					
DE	4,138	1,112	3	0.27%					
MA	34,376	8,890	15	0.17%					
MD	25,339	6,569	41	0.62%					
ME	4,490	1,259	6	0.48%					
NH	5,948	1,533	3	0.20%					
NJ	37,160	8,890	23	0.26%					
OH	36,177	10,290	20	0.19%					
RI	3,694	773	-	0.00%					
VT	2,897	784	2	0.26%					
NY	70,721	14,590	22	0.15%					
QIN	242,174	58,843	149	0.25%					



8

Data Claims Analysis: Community Beneficiaries Lacking Medication-Assisted Treatment (MAT)

Results indicate very low MAT prescribing in both community and nursing home (next slide) populations.

Medicare FFS Community-Eligible Population of Beneficiaries Diagnosed with OUD, without MAT claims

Medicare FFS Community-Eligible Population of Beneficiaries Diagnosed with OUD, with MAT claims

	OUD	nosed	with eived	Pa wi	OUD itients ithout MAT	Pa	OUD tients ithout MAT	Had Buprenorphine Prescription	Had Buprenorphine /Naloxone Prescription	Had Naltrexone Prescription							Pi	lad MAT rocedure Code ethadon		% Had MAT Procedure Code Methadone	Had MAT Procedure Code Buprenorphine	% Had MAT Procedure Code Buprenorphine	
QIN	5	0,34	3	41	1,933	83	8.29%	9,936	2,760	540													
											Q	IN		7,977		15.85%	454	0.90%					
N	ledicare FFS Comn e Total Beneficiaries Diagnosed with OUD or		le Population without MAT % OUD Patients without MAT		es Diagnosed wi Had Buprenorphine /Naloxone Prescription	ith OUD, Had Naltrexone Prescription					Medicare FFS (State	Community- Eligible Had MAT Procedure Code Methadone	e Beneficiaries Dia % Had MAT Procedure Code Methadone	gnosed with OUD wi Had MAT Procedure Code Buprenorphine	th MAT claims % Had MAT Procedure Code Buprenorphine								
	Received MAT				·						CT	543 86	21.87% 14.78%	- 1	0.00%								
СТ		1,939	78.09%	380	179	26					DC DE	108	4.34%	1	0.17%								
DC	582	495	85.05%	79	59	4					MA	1,959	22.27%	3	0.03%								
DE		2,369	95.29%	173	72	10					MA	1,935	20.30%	121	1.27%								
MA		6,827	77.62%	2,784	1,560	150					ME	310	20.30%	3	0.20%								
ME		7,474	78.57% 79.53%	1,300 539	727	67 14					NH	357	17.74%	8	0.40%								
NH	2,012	1,216	79.53% 81.96%	539	30	14					NJ	801	17.74%	33	0.40%								
NJ		7,120	89.57%	962	11	56					OH	299	5.94%	219	4.35%								
OH		4,511	89.63%	916	16	74					RI	109	21.76%	13	2.59%								
RI		377	75.25%	133	5	4					VT	278	23.44%	33	2.78%								
VT		879	74.11%	488	15	11		Data Source: M	ledicare Fee For		NY	1,196	14.45%	9	0.11%								
NY		7,077	85.52%	1,607	70 2,760	106		Data Source. IV	ieuicale ree FOI		QIN	7,977	15.85%	454	0.90%		CMS 2024						
QI	I 50,343	41,933	83.29%	9,936	2,760	540		Service (FFS) Pa 10-1-22 throug	rts A, B, and D (h 9-30-23.	claims,	QUT	,,,,,	190970	1.01	015070		k Quality	ranca	y -				

9

Resilient and Ready Together

Data Claims Analysis: Nursing Home (NH) Beneficiaries Lacking MAT

Medicare FFS NH-Eligible Population of Beneficiaries Diagnosed with OUD, without MAT claims

Medicare FFS NH-Eligible Population of Beneficiaries Diagnosed with OUD, with MAT claims

																-			
	Dia	Total (Residents Diagnosed with OUD or Received MAT)		n Re	OUD Residents without MAT	s Re	% OUD esidents I without MAT	Had Buprenorphine Prescription	Had Buprenorphine /Naloxone Prescription	Had Naltrexone Prescription		Had MA Procedu Code Methado		e	% Had M/ Procedur Code Methador	re	Had MAT Procedure Code Buprenorphine	% Had I Proced Code Buprenor	ure e
QIN		3,3	33	3	8,026	9	0.79%	319	82	29									
		0,0			,010		••••••	010	-		QIN		294		8.82%	6	15	0.45	%
																-			
M	Iedicare FFS N Total (Residents		without MAT o % OUD		iagnosed with O Had Buprenorphine	UD, Had Naltrexone					Medicare F	FFS NH- Eligible Be	neficiaries Diagnos	ed with OUD with	MAT claims				
	Diagnosed	without		Prescription		Prescription					State	Had MAT	% Had MAT	Had MAT	% Had MAT				
	with OUD	MAT	MAT		Prescription							Procedure Code	Procedure Code	Procedure Code	Procedure Code				
	or Received MAT)										СТ	Methadone 14	Methadone 5.71%	Buprenorphine	Buprenorphine 0.00%				
СТ	245	231	94.29%	31	14	4					DC	8	16.67%	-	0.00%				
DC	48	40	83.33%	1	-	÷					DE	2	2.20%	-	0.00%				
DE	91	89	97.80%	1	-	1					MA	43	8.37%	-	0.00%				
MA	514	471	91.63%	75	40	8	4				MD	91	13.58%	7	1.04%				
MD	670	572	85.37%	59	27	3					ME	1	1.56% 1.33%	-	0.00%				
ME	64 75	63 74	98.44% 98.67%	5	-	1	4				NH	46	7.01%		0.00%				
NH	656	610	98.67%	60	-	- 5					OH	-+0	2.49%	6	1.87%				
OH	321	307	95.64%	32	1	-	4				RI	5	12.20%	2	4.88%		MS 2024		
RI	41	34	82.93%	2	-	1		Data Source: Me	edicare Fee For		VT	1	4.00%	•	0.00%				
VT	25	24	96.00%	3			1				NY	74	12.69%		0.00%				
NY	583	511	87.65%	47	-	6		Service (FFS) Par	ts A, B, and D clain	ns,	QIN	294	8.82%	15	0.45%				-
QIN	3,333	3,026	90.79%	319	82	29		10-1-22 through	9-30-23								Confára		
							-		5 50-25.							T		HICE	10

10

Resilient and Ready Together

Disseminate Best Practice Resources and Call to Action

In 2023 IPRO convened PALTC stakeholders for action:

- Created Nursing Home Naloxone Toolkit.
- Resources provided on Medications for Opioid Use Disorder (MOUD) and for naloxone advocacy in the region.
- Included the NYS DOH, BNE, OASAS, provider associations and pharmacy organizations.

2024 plans include a webinar instructional series on the implementation of medications for OUD that meets the needs and concerns of SNF/PALTC facilities:

 Provide data-driven technical assistance to nursing homes emphasizing naloxone, medications for OUD, and alternatives to opioids.

Abbreviations: QIN-QIO: Quality Innovation Network-Quality Improvement Organization; SNF: Skilled Nursing Facility; PALTC: Post-Acute Long-Term Care; NYS: New York State; DOH: Department of Health; BNE: Bureau of Narcotic Enforcement; OASAS: Office of Addiction Services and Support; OUD: Opioid Use Disorder



Resilient and Ready Together

11



Opioid Treatment Policy Progress: Challenges and Opportunities

Karran Phillips, MD, MSc


Deputy Director, Center for Substance Abuse and Treatment

Substance Abuse and Mental Health Services Administration (SAMHSA)


US Department of Health and Human Services



Opioids are driving drug overdose deaths – more than 109,000 in 2022



Legend for Drug or Drug Class





A National Snapshot of Substance Use Disorders



- Overdose remains a leading cause of injury-related death, with more than 109,000 lives lost (Jan. 2023).
 - In 2022, provisional data found 68% of the 107,000 fatal overdoses involved synthetic opioids, primarily illicitly manufactured fentanyl.
 - **Xylazine** is an adulterant increasingly found in the illicit drug supply.
 - January–December 2021, a total of 5.3% of overdose deaths had xylazine detected on postmortem toxicology
 - Xylazine was listed as a cause of death in 79.0% of deaths in which it was detected
 - Stimulants are increasingly adulterated with illicitly manufactured fentanyl.
 - In 2021, 81.9% of deaths involved at least one opioid and 54.2% involved at least one stimulant
- Among people 12 or older in 2022, 59.8% (or 168.7 million people) used tobacco, alcohol, or an illicit drug in the past month. 16.5% (or 46.6 million people) reported use of an illicit drug.
- 19.4 percent of people 12 or older in 2022 (54.6 million) felt that they needed treatment.
- **72% of adults** who had a substance use problem considered themselves to be in recovery or recovering.



Guiding Federal Frameworks

HHS Overdose Prevention Strategy




https://www.hhs.gov/overdose-prevention/




HHS.gov


White House Strategy



https://bit.ly/3ulQ9Gl







Addressing Overdose through Improved Policy: MAT and MATE Acts - 2023

- Policy changes are presenting new opportunities
- DEA temporarily extended the COVID-19 telemedicine flexibilities to prescribe controlled medications
- FDA approved **over-the-counter** naloxone nasal spray
- President Biden signed into law H.R.
 2617, the "Consolidated Appropriations Act, 2023"

Mainstreaming Addiction	Medication Access and
Treatment (MAT) Act	Training Expansion Act (MATE)
Removes the DATA-2000 Waiver to prescribe buprenorphine	Requirement for a non-recurring, 8-hour training on SUD for practitioners applying for registration from the DEA
Lifts caps on number of patients who	Met through addiction board
can be treated; removes counseling	certification, as part of or post-health
and reporting requirements	care professional degree training

Implementation of MAT and MATE requires close collaboration and coordination between the Department of Justice/Drug Enforcement Administration, and Health and Human Services/SAMHSA



Addressing Overdose through Improved Policy: Changes to 42 CFR Part 8 – Published February 2nd, 2024

- In 2001, regulations governing methadone treatment for Opioid Use Disorder (OUD) shifted from FDA to SAMHSA
- SAMHSA reduced the scope of regulations that had been in place since 1972, but retained many original restrictions on methadone treatment
- These restrictions posed barriers to patient enrollment, but many factors precluded revisions
- The COVID-19 pandemic necessitated quickly creating regulatory flexibilities in key areas
 - Expanded parameters of take-home methadone dosing
 - Initiation of buprenorphine via telehealth
- The ongoing overdose crisis calls for patient-centered, accessible care
- Feedback from multiple stakeholder groups request and/or endorse continuation of the flexibilities and other changes to the rules



Ongoing Challenges: Eradicating Stigma


SUDs carry a high burden of stigma

- People with SUD are
 - less likely to seek treatment
 - more likely to drop out of treatment
- SUD is among the most stigmatized conditions in the US and around the world
- Health care providers treat patients who have SUDs differently
- People with a SUD who expect or experience stigma have poorer outcomes





Ongoing Challenges: Overcoming Provider Reluctance to Treat



https://www.samhsa.gov/practitioner-training



Opportunities

- Where reimbursement is appropriate, and easily obtained, practitioners are more likely to provide services, and expand access
- The OTPs may be concerned that the revised rules will impact their fiscal viability, given reduced take homes and removal of ability to require counseling, however, the rules foster coordination of care and collaboration with other services.
- How can CMS help:
 - Educate OTPs on ancillary billing codes available to them under both Medicare and Medicaid that will support collaboration and provision of primary medical care and behavioral health services
 - Expand education to reviewers to familiarize them with OTP services
 - Help standardize how Medicaid is applied across states vis-à-vis OTPs
 - Encourage State Medicaid Directors to
 - a) attend the planned webinars on Part 8 rollout
 - ▲ b) increase understanding of the needs of the OTPs in their states



Thank you!

SAMHSA's mission is to lead public health and service delivery efforts that promote mental health, prevent substance misuse, and provide treatment and supports to foster recovery while ensuring equitable access and better outcomes.



FindSupport.gov

FindTreatment.gov

988Lifeline.org

www.SAMHSA.gov

1-877-SAMHSA7 (1-877-726-4727)

1-800-487-4889 (TDD)





HRSA Federal Office of Rural Health Policy Resources for Rural Communities

Megan Meacham, MPH Director, Rural Strategic Initiatives Division Federal Office of Rural Health Policy Health Resources and Services Administration (HRSA) US Department of Health and Human Services



Health Resources and Services Administration



Mission: To improve health outcomes and achieve health equity through access to quality services, a skilled health workforce, and innovative, high-value programs



TENS OF MILLIONS of Americans receive quality, affordable health care, and other services through HRSA's 90-PLUS PROGRAMS and more than 3,000 GRANTEES



HRSA Program Areas









Maternal & Child Health



Provider Relief



Health Workforce



National Health Service Corps



Rural Health



Ryan White HIV/AIDS Program







Organ Donation & Transplantation



Behavioral Health Initiatives



In FY 23, HRSA invested over **\$2 billion** for behavioral health initiatives that improves access to behavioral health services for individuals in underserved and rural communities across the nation.

As a result:

- HRSA awarded \$25 million to 77 HRSA-funded health centers to create new and expand existing school-based health centers, which for the first-time included support for these school health centers to provide mental health services in schools.
- Approximately 3,700 rural health clinicians provide behavioral health services through the National Health Service Corps (NHSC)
- 21 Behavioral health workforce programs provide education and training to the workforce
- More than 8,700 behavioral health providers are supported by NHSC loan repayment programs
- 14 suicide prevention and 40 overdose prevention programs connect people to care and contribute to saving lives.



The Federal Office of Rural Health Policy




27

The Federal Office of Rural Health Policy collaborates with rural communities and partners to support community programs and shape policy that will improve health in rural America.

Activities:

- Align federal initiatives
- Build capacity
- Advise the Secretary of Health and Human Services



Rural Communities Opioid Response Program





One of 22 naloxone safety kits installed in libraries throughout MI's northern Lower Peninsula as part of MI Center for Rural Health's RCORP grant

Participants of a Mental Health First Aid training hosted by Bay Rivers Telehealth Alliance in VA



- The <u>Rural Communities Opioid Response Program</u> (RCORP) provides direct funding and technical assistance to rural communities to address behavioral health workforce and service delivery needs, including SUD/OUD.
- Through RCORP, grantees have served in 47 states and 2 territories, reaching 1,900+ rural counties.
- RCORP grant recipients are providing direct services to more than 2 million rural patients per year.
- RCORP programs continue to expand to more diverse and emerging areas.



Rural Communities Opioid Response Program Rural Centers of Excellence on SUD



Recovery Center of Excellence

RCOE on Prevention: University of Rochester

- Reduce morbidity and mortality related to SUD by focusing on prevention activities
- Working to engage communities/ reduce stigma, save lives, and support primary care

Find us at: recoverycenterofexcellence.org



RCOE on Treatment: University of Vermont

- Expanding evidence-based treatment and harm reduction for OUD and other SUDs via education, technical assistance, and resources
- Patient focused approaches serving the needs of rural populations through innovative technology and telehealth strategies

Find us at: <u>www.uvmcora.org</u> or <u>cora@uvm.edu</u>





RCOE on Recovery: Fletcher Group

- Expansion of Recovery Housing Capacity & Quality
- Rural Recovery Ecosystem Support Services: Employment, Housing, Transportation
- Evidenced-Based Education & Training

Find us at: <u>www.fletchergroup.org</u>



29

RCORP Funding Opportunities Forecast (Pending Appropriations)



Program	FY 2024	FY 2025
RCORP-Overdose Response		NOFO Available: Fall 2024/Winter 2025 Project Start Date: 9/1/2025
RCORP-Stimulant Support	NOFO Available: Spring 2024 Project Start Date: 9/1/2024	
RCORP-Impact	NOFO Available: Winter/Spring 2024 Project Start Date: 9/1/2024	



Rural Health Support – Assistance and Services



- Telehealth Centers of Excellence
 - www.telehealthcoe.org
- Telementoring Training Center
 - www.ruraltelementoring.org
- 3RNet Rural Recruiting and Retention Network
 - www.3Rnet.org
- Rural Emergency Hospital National Technical Assistance Center
 - Rural Health Redesign Center <u>www.rhrco.org/reh-tac</u>
- Partnerships
 - National Organizations of State Offices of Rural Health <u>www.nosorh.org</u>
 - National Rural Health Association <u>www.ruralhealth.us</u>



31

Rural Health Support – Free Resources



- Rural Health Information Hub topic guides, data, maps, case studies, and toolkits
 - www.ruralhealthinfo.org
- Rural Research Gateway
 - www.ruralhealthresearch.org
- Rural Residency and Training Resources
 - www.RuralGME.org
 - www.rttcollaborative.net
- Rural Health Value research and resources about value-based payment
 - ruralhealthvalue.public-health.uiowa.edu
- AgriSafe Resources occupational and public health
 - www.agrisafe.org



Subscribe to FORHP Weekly Announcements





Announcements from the

Federal Office of Rural Health Policy

Having trouble viewing this email? View it as a webpage

May 18, 2023

What's New

Funding Now Available for the Rural Maternity and Obstetrics Management Strategies Program. On Tuesday, HRSA announced that the Rural Maternity and Obstetrics Management Strategies Program (RMOMS) is accepting applications through Friday, July 7. Approximately \$2 million is available to fund up to two health networks to preserve access to and continuity of maternal and obstetrics care in rural communities. For more information about the RMOMS program and current awardees, visit the RMOMS webpage.

<u>Stigma and Opioid Use Disorder</u>. More than 450 clinicians and counselors in rural New England were surveyed about stigma as a barrier to treating patients for opioid used disorder (OUD) as well as practitioners' beliefs about medications for OUD. Over half (55 percent)

https://www.hrsa.gov/about/organization/bureaus/forhp





Connect with HRSA

Learn more about our agency at: www.HRSA.gov



FOLLOW US:





34



Medicare: Opioid Use Disorder Treatment

CDR Wanda Pamphile, PharmD, MPH Outreach Specialist, Region 2 (New York) Office of Program Operations and Local Engagement Centers for Medicare and Medicaid Services (CMS) US Department of Health and Human Services



Medicare Opioid Use Disorder Screening & Treatment

- Medicare pays for opioid use disorder (OUD) screenings performed by physicians and non-physician practitioners.
- Screening for OUD is a required element of Medicare's Initial Preventive Physical Exam and Annual Wellness Visit.
- During visits in physicians' offices and outpatient hospital settings, Medicare will pay for Screening, Brief Intervention, & Referral to Treatment (SBIRT) treatment services.

https://www.cms.gov/medicare/payment/fee-schedules/physician-fee-schedule/opioid-use-disorder-screening-treatment



36

Medicare Opioid Use Disorder Treatment

Medicare will pay for certain treatment services:

Evaluation & Management (E/M) visits for medication management

You can use E/M visits to provide medication management to make sure patients take medications properly as part of their recovery process.

Office-based Substance Use Disorder (SUD) treatment services

Medications prescribed as part of in-office treatment could include buprenorphine and naltrexone. If your patient has Medicare Part D coverage, these medications may be covered by their plan.

Opioid Treatment Program (OTP) (a more comprehensive treatment)

OTPs provide medication-assisted treatment (MAT) for people diagnosed with an opioid use disorder (OUD). OTPs must be certified by SAMHSA and accredited by an independent, SAMHSA-approved accrediting body.

https://www.cms.gov/medicare/payment/fee-schedules/physician-fee-schedule/opioid-use-disorder-screening-treatment



37

Opioid Treatment Program (OTP) Services

- Medicare covers opioid use disorder (OUD) treatment services in opioid treatment programs (OTPs) through bundled OUD Medicare Part B treatment services payments.
- There's NO copayment for OTP services for Medicare patients, but the Part B deductible does apply.
- The services include:
 - FDA-approved opioid agonist and antagonist medications for opioid use disorders (MOUD) including methadone, buprenorphine, and naltrexone and their administration (if applicable)
 - Dispensing and administering MOUD medications FDA-approved opioid antagonist medications, specifically naloxone, for emergency treatments of opioid overdose, as well as overdose education provided in conjunction with opioid antagonist medication
 - Substance use counseling
 - Individual and group therapy
 - Toxicology testing
 - Intake activities
 - Periodic assessments that OTPs may conduct via two-way interactive audio-video communication technology





Telehealth Services for Opioid Use Disorder (OUD) Treatment

- During the public health emergency, CMS covered telehealth-based OUD treatment at the same rates as in-person service.
- CMS permanently extended some telehealth policies for mental health and OUD:
 - Medicare covers video or audio-based treatment that people receive in their homes and other locations
 - For people who cannot use video, CMS will pay for audio-only mental health services (including those for OUD)
- Fiscal Year (FY) 2023 Medicare Physician Fee Schedule (MPFS) final rule allowed the OTP intake add-on code to be furnished via two-way audio-video communications technology when billed for the initiation of treatment with buprenorphine
- Also allowed periodic assessments to be furnished audio-only when video is not available for the duration of Calendar Year (CY) 2023
- FY 2024 MPFS proposed rule proposes to extend flexibilities through CY 2024

https://www.cms.gov/medicare/payment/opioid-treatment-program/billing-payment



Contact Information

CDR Wanda Pamphile, PharmD, MPH 26 Federal Plaza, 18th Floor New York, NY 10278 Email: <u>wanda.pamphile1@cms.hhs.gov</u>



Feedback

Thank you for attending today's session. We appreciate your time. We are always trying to improve our level of service to our customers and stakeholders. You can help us do that by providing your feedback on today's session. Please take a few moments to complete this brief evaluation via link or QR code. Thank you very much.

Please use this name for the CMS Activity: **April 9, 2024** – HHS' Call to Action on Opioid Use Disorder Treatment

https://cmsgov.force.com/act/Evaluation



Resilient and Ready Together